MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...
On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...
Morning Overview on MSN
Programmable CRISPR cuts stem cell timing from months to weeks
Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
The answer is yes, absolutely, absolutely 100%. but it's not all kinds of math, and it's not all kinds of programming. that ...
Bedford ‘s Nicole Steele, a biochemistry and molecular biology major at Clark University, is part of a team working with the ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
Investor's Business Daily on MSN
Stocks to watch: CRISPR Therapeutics sees relative strength rating rise to 82
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...
The field of dermatology has witnessed remarkable progress in the prevention and treatment of skin diseases over the past ...
Of the 11 patients treated with BE-CAR7 T cells, seven are in remission, including one patient who has been in remission for three years.
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback